Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1982 Jul;22(1):36–42. doi: 10.1128/aac.22.1.36

Ceftriaxone (Ro 13-9904) therapy of serious infection.

R W Bradsher
PMCID: PMC183670  PMID: 6289739

Abstract

Ceftriaxone (Ro 13-9904), a newly developed cephalosporin with a long half-life, was evaluated for efficacy and safety in 19 patients with serious infections. Underlying illnesses were present in 16 patients. Ceftriaxone was given intravenously every 12 h. Infections treated included gram-negative bacillary pneumonias (two cases), staphylococcal and streptococcal soft tissue-skeletal infections (six cases), spontaneous peritonitis (two cases), and complicated urinary tract infections (nine cases). Bacteremia was present in three patients. Microbiological and clinical cures were achieved in all but one case, although three patients with urinary infection had recurrences 6 weeks posttherapy. The only failure occurred in a patient with pneumonia who had a Pseudomonas aeruginosa isolated from sputum with an initial minimal inhibitory concentration of 4 micrograms/ml, but after 9 days of therapy, a repeat isolate had a minimal inhibitory concentration of 32 micrograms/ml. The minimal inhibitory concentrations for the other isolates ranged from less than or equal to 0.6 to 8.0 micrograms/ml. The mean peak plasma level of ceftriaxone was 99.9 micrograms/ml. The only side effects noted were drug fever in one patient, phlebitis in two patients, and thrombocytosis in four patients.

Full text

PDF
36

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennett J. V., Brodie J. L., Benner E. J., Kirby W. M. Simplified, accurate method for antibiotic assay of clinical specimens. Appl Microbiol. 1966 Mar;14(2):170–177. doi: 10.1128/am.14.2.170-177.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beskid G., Christenson J. G., Cleeland R., DeLorenzo W., Trown P. W. In vivo activity of ceftriaxone (Ro 13-9904), a new broad-spectrum semisynthetic cephalosporin. Antimicrob Agents Chemother. 1981 Aug;20(2):159–167. doi: 10.1128/aac.20.2.159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Eickhoff T. C., Ehret J. Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative. Antimicrob Agents Chemother. 1981 Mar;19(3):435–442. doi: 10.1128/aac.19.3.435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hinkle A. M., Bodey G. P. In vitro evaluation of Ro 13-9904. Antimicrob Agents Chemother. 1980 Oct;18(4):574–578. doi: 10.1128/aac.18.4.574. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Landesman S. H., Corrado M. L., Cherubin C. E., Sierra M. F. Activity of moxalactam and cefotaxime alone and in combination with ampicillin or penicillin against group B streptococci. Antimicrob Agents Chemother. 1981 May;19(5):794–797. doi: 10.1128/aac.19.5.794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Louie T. J., Bartlett J. G., Tally F. P., Gorbach S. L. Aerobic and anaerobic bacteria in diabetic foot ulcers. Ann Intern Med. 1976 Oct;85(4):461–463. doi: 10.7326/0003-4819-85-4-461. [DOI] [PubMed] [Google Scholar]
  7. McKendrick M. W., Geddes A. M., Wise R., Bax R. Cefotaxime in septicaemia including typhoid fever. J Antimicrob Chemother. 1980 Sep;6 (Suppl A):277–281. doi: 10.1093/jac/6.suppl_a.277. [DOI] [PubMed] [Google Scholar]
  8. Neu H. C., Meropol N. J., Fu K. P. Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin. Antimicrob Agents Chemother. 1981 Mar;19(3):414–423. doi: 10.1128/aac.19.3.414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Petty B. G., Smith C. R., Wade J. C., Conrad G. L., Lipsky J. J., Ellner J. J., Lietman P. S. Double-blind comparison of cefamandole and penicillin in pneumococcal pneumonia. Antimicrob Agents Chemother. 1978 Jul;14(1):13–18. doi: 10.1128/aac.14.1.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Seddon M., Wise R., Gillett A. P., Livingston R. Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1980 Aug;18(2):240–242. doi: 10.1128/aac.18.2.240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Stevens D. L., Haburchak D. R., McNitt T. R., Everett E. D. Group B streptococcal osteomyelitis in adults. South Med J. 1978 Nov;71(11):1450–1451. doi: 10.1097/00007611-197811000-00046. [DOI] [PubMed] [Google Scholar]
  12. Tofte R. W., Rotschafer J., Solliday J., Crossley K. B. Moxalactam therapy for a wide spectrum of bacterial infections in adults. Antimicrob Agents Chemother. 1981 May;19(5):740–744. doi: 10.1128/aac.19.5.740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Trager G. M., Panwalker A. P., Malow J. B., Porembski P. E., Ramirez C. A., Zar F. A. Clinical efficacy of moxalactam with emphasis on infections due to multidrug-resistant organisms in patients with renal insufficiency. Chemotherapy. 1981;27(4):287–295. doi: 10.1159/000237993. [DOI] [PubMed] [Google Scholar]
  14. Wise R., Gillett A. P., Andrews J. M., Bedford K. A. Ro 13-9904: A cephalosporin with a high degree of activity and broad antibacterial activity: an invitro comparative study. J Antimicrob Chemother. 1980 Sep;6(5):595–600. doi: 10.1093/jac/6.5.595. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES